全文获取类型
收费全文 | 4700篇 |
免费 | 279篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 92篇 |
妇产科学 | 66篇 |
基础医学 | 775篇 |
口腔科学 | 53篇 |
临床医学 | 410篇 |
内科学 | 1088篇 |
皮肤病学 | 105篇 |
神经病学 | 191篇 |
特种医学 | 300篇 |
外科学 | 588篇 |
综合类 | 48篇 |
预防医学 | 201篇 |
眼科学 | 85篇 |
药学 | 531篇 |
中国医学 | 64篇 |
肿瘤学 | 365篇 |
出版年
2023年 | 19篇 |
2022年 | 83篇 |
2021年 | 126篇 |
2020年 | 66篇 |
2019年 | 98篇 |
2018年 | 127篇 |
2017年 | 97篇 |
2016年 | 159篇 |
2015年 | 192篇 |
2014年 | 284篇 |
2013年 | 304篇 |
2012年 | 445篇 |
2011年 | 442篇 |
2010年 | 305篇 |
2009年 | 248篇 |
2008年 | 299篇 |
2007年 | 319篇 |
2006年 | 253篇 |
2005年 | 251篇 |
2004年 | 207篇 |
2003年 | 165篇 |
2002年 | 156篇 |
2001年 | 33篇 |
2000年 | 24篇 |
1999年 | 25篇 |
1998年 | 53篇 |
1997年 | 38篇 |
1996年 | 26篇 |
1995年 | 19篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 13篇 |
1988年 | 13篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 11篇 |
1981年 | 6篇 |
1980年 | 13篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1972年 | 3篇 |
1971年 | 7篇 |
1969年 | 3篇 |
排序方式: 共有5059条查询结果,搜索用时 15 毫秒
1.
Andy KH Lim 《World journal of gastroenterology : WJG》2020,26(10):1020-1028
Rhabdomyolysis is a syndrome of skeletal muscle injury with release of cellular constituents such as potassium,phosphate,urate and intracellular proteins such as myoglobin into the circulation,which may cause complications including acute kidney injury,electrolyte disturbance and cardiac instability.Abnormal liver function tests are frequently observed in cases of severe rhabdomyolysis.Typically,there is an increase in serum aminotransferases,namely aspartate aminotransferase and alanine aminotransferase.This raises the question of liver injury and often triggers a pathway of investigation which may lead to a liver biopsy.However,muscle can also be a source of the increased aminotransferase activity.This review discusses the dilemma of finding abnormal liver function tests in the setting of muscle injury and the potential implications of such an association.It delves into some of the clinical and experimental evidence for correlating muscle injury to raised aminotransferases,and discusses pathophysiological mechanisms such as oxidative stress which may cause actual liver injury.Serum aminotransferases lack tissue specificity to allow clinicians to distinguish primary liver injury from muscle injury.This review also explores potential approaches to improve the accuracy of our diagnostic tools,so that excessive or unnecessary liver investigations can be avoided. 相似文献
2.
3.
4.
王伏虎 《南京医科大学学报(英文版)》2002,16(2):49-64
Stroke is a debilitating disease that affects millions each year.While in many cases cerebral ischemic in jury can be limited by effectivw resuscitation or thrombolytic treatment,the injured neurons wither in a process known as delayed neuronal death(DND).Mounting evidence indicates that DND is not simply necrosis played out in slow motion but apoptosis is triggered.Of particular interest are two groups of signal proteins that participate in apoptosis-cyclin dependent kinases(CDKs) and p53-among a myriad of signaling events after an ischemic insult.Recent investigations have shown that CDKs,a family of enzymes initially known for their role in cell cycle regulation,are activated in injured neurons in DND.As for p53,new reports suggest that its up-regulation may represent a failed attempt to rescue in jured neurons,although its up-regulation was previously considered an indication of apoptosis.These observations thus rekindle an old quest to identify new neuroprotective targets to minimize the stroke damage.In this review,the author will examine the evidence that indicates the participation of CDKs and p53 in DND and then introduce pre-clinical data to explore CDK inhibition as a potential neuroprotective target.Finally,using CDK inhibition as an example,this paper will discuss the pertinent criteria for a viable neuroprotective strategy for ischemic in jury. 相似文献
5.
Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: a prospective trial in renal transplants 总被引:2,自引:0,他引:2
Yu Seun Kim Myoung Soo Kim Soon Il Kim Seung Kil Lim Ho Yung Lee Dae Suk Han Kiil Park 《Transplant international》1997,10(3):197-201
It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes
mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional
steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort
in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort
would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone
(the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy
of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group,
patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period
of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose
control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects
were clearly evident in the post-Tx DM patients. More than 50 % dose reduction of blood glucose-lowering agents was possible
in 42.3 % of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients
without seriously affecting the immunosuppressive activity after conversion to deflazacort.
Received: 20 August 1996 Received after revision: 25 November 1996 Accepted: 6 December 1996 相似文献
6.
7.
8.
Bum Soon Choi Mi Jung Shin Suk Joon Shin Young Soo Kim Yeong Jin Choi Yong-Soo Kim In Sung Moon Suk Young Kim Yong Bok Koh Byung Kee Bang Chul Woo Yang 《American journal of transplantation》2005,5(6):1354-1360
We report here our 10-year experience of a biopsy performed at day 14 after transplantation in 304 patients with stable graft function. The factors that may have influenced subclinical rejection were analyzed according to histology. The incidence of subclinical rejection was 13.2%. Addition of mycophenolate mofetile (MMF) as a primary immunosuppressant significantly decreased the incidence of subclinical rejection compared with patients without such treatment (odds ratio, 0.23; p < 0.05). On the other hand, HLA-DR antigen mismatch (odds ratio, 2.39) and unrelated donor (odds ratio, 2.10) were also significantly associated with decreased subclinical rejection (p < 0.05). The incidence of acute rejection in patients with normal findings was lower than in those with borderline changes or subclinical rejection (0.23 +/- 0.05 vs. 0.48 +/- 0.07 and 0.60 +/- 0.11, respectively; p < 0.05). The graft survival rates in patients with subclinical rejection were lower than in patients with normal or borderline changes at 1 (88.4% vs. 97.9% and 99.1%; p < 0.05), 5 (77.8% vs. 96.2% and 95.9%; p < 0.05) and 10 (62.3% vs. 96.2% and 93.7%; p < 0.05) years. Thus, a protocol biopsy performed on day 14 after transplantation is useful for predicting graft survival. Triple therapy including MMF, related donor and HLA-DR antigen match are important factors for reducing subclinical rejection in living-donor renal transplantation. 相似文献
9.
10.